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Abstract
Elevation of intracellular Ca21 concentration induces the synthesis of N-arachydonoylethanolamine
(anandamide) in a subpopulation of primary sensory neurons. N-acylphosphatidylethanolamine
phospholipase D (NAPE-PLD) is the only known enzyme that synthesizes anandamide in a Ca21-
dependent manner. NAPE-PLD mRNA as well as anandamide’s main targets, the excitatory tran-
sient receptor potential vanilloid type 1 ion channel (TRPV1), the inhibitory cannabinoid type 1
(CB1) receptor, and the main anandamide-hydrolyzing enzyme fatty acid amide hydrolase (FAAH),
are all expressed by subpopulations of nociceptive primary sensory neurons. Thus, NAPE-PLD,
TRPV1, the CB1 receptor, and FAAH could form an autocrine signaling system that could shape the
activity of a major subpopulation of nociceptive primary sensory neurons, contributing to the devel-
opment of pain. Although the expression patterns of TRPV1, the CB1 receptor, and FAAH have
been comprehensively elucidated, little is known about NAPE-PLD expression in primary sensory
neurons under physiological and pathological conditions. This study shows that NAPE-PLD is
expressed by about one-third of primary sensory neurons, the overwhelming majority of which also
express nociceptive markers as well as the CB1 receptor, TRPV1, and FAAH. Inflammation of
peripheral tissues and injury to peripheral nerves induce differing but concerted changes in the
expression pattern of NAPE-PLD, the CB1 receptor, TRPV1, and FAAH. Together these data indi-
cate the existence of the anatomical basis for an autocrine signaling system in a major proportion of
nociceptive primary sensory neurons and that alterations in that autocrine signaling by peripheral
pathologies could contribute to the development of both inflammatory and neuropathic pain.
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1 | INTRODUCTION
N-arachidonoylethanolamine (anandamide) is a lipid signaling molecule
(Devane et al., 1992) that is synthesized both in a Ca21-insensitive and in
a Ca21-sensitive manner through multiple enzymatic pathways and a sin-
gle pathway that involves the activity of N-acylphosphatidylethanolamine
phospholipase D (NAPE-PLD; Okamoto, Morishita, Tsuboi, Tonai, &
Ueda, 2004; Ueda, Liu, & Yamanaka, 2001; Wang et al., 2006; Wang,
Okamoto, Tsuboi, & Ueda, 2008). Although anandamide acts on a series
of molecules, the transient receptor potential vanilloid type 1 ion channel
(TRPV1; Caterina et al., 1997) and the cannabinoid 1 (CB1) receptor (Mat-
suda, Lolait, Brownstein, Young, & Bonner, 1990) are believed to be anan-
damide’s main targets (Devane et al., 1992; Zygmunt et al., 1999).
Activation of TRPV1 results in the opening of this nonselective cationic
channel and subsequent excitation of nociceptive primary sensory neu-
rons, whereas activation of the CB1 receptor is believed to produce an
inhibitory effect that includes the inhibition of L-, P/Q-, and N-type volt-
age-gated Ca21 channels in neurons, including primary sensory neurons
(Caterina et al., 1997; Mackie & Hille, 1992; Mackie, Lai, Westenbroek, &
Mitchell, 1995; Tominaga et al., 1998; Twitchell, Brown, & Mackie, 1997).
The CB1 receptor and TRPV1 are coexpressed by various neurons,
including a great proportion of nociceptive primary sensory neurons
(Agarwal et al., 2007; Ahluwalia, Urban, Capogna, Bevan, & Nagy, 2000;
Binzen et al., 2006; Mitrirattanakul et al., 2006). This anatomical arrange-
ment allows exogenous anandamide to control the activity of neurons,
including a major group of nociceptive primary sensory neurons (Ahluwa-
lia, Urban, Bevan, & Nagy, 2003).
Anandamide is synthesized in subpopulations of primary sensory
neurons in both Ca21-sensitive and Ca21-insensitive manners (van der
Stelt et al., 2005; Varga et al., 2014; Vellani et al., 2008). Consistent
with the ability of a group of primary sensory neurons to synthesize
anandamide in a Ca21-sensitive manner (van der Stelt et al., 2005) and
the role of NAPE-PLD in such anandamide synthesis (Okamoto et al.,
2004; Ueda et al., 2001; Wang et al., 2006, 2008), NAPE-PLD mRNA is
expressed by primary sensory neurons (Nagy et al., 2009). Most of the
NAPE-PLD mRNA-expressing cells are capsaicin sensitive (Nagy et al.,
2009), so they should also express TRPV1 and the CB1 receptor (Agar-
wal et al., 2007; Ahluwalia et al., 2000; Binzen et al., 2006; Mitriratta-
nakul et al., 2006). Therefore, in addition to exogenous anandamide,
anandamide of primary sensory neuron origin could also be able to
control TRPV1 and CB1 receptor activity in a major subpopulation of
nociceptive primary sensory neurons in an autocrine manner (van der
Stelt & Di Marzo, 2005; van der Stelt et al., 2005).
In addition to NAPE-PLD and the CB1 receptor, the great majority
of TRPV1-expressing primary sensory neurons also express the main
anandamide-hydrolyzing enzyme fatty acid amide hydrolase (FAAH;
Cravatt et al., 1996; Lever et al., 2009). Blocking FAAH activity through
increasing the level of anandamide also results in regulating the activity
of a proportion of nociceptive primary sensory neurons through the
CB1 receptor and TRPV1 (Lever et al., 2009). Based on the coexpres-
sion pattern of TRPV1, the CB1 receptor, NAPE-PLD, FAAH, and the
effects of those molecules, the presence of an endocannabinoid/endo-
vanilloid autocrine signaling system built by those molecules has been
proposed in a major subpopulation of nociceptive primary sensory neu-
rons (Sousa-Valente, Varga, Ananthan, Khajuria, & Nagy, 2014; van der
Stelt & Di Marzo, 2005; van der Stelt et al., 2005). That autocrine sig-
naling system, through TRPV1- and CB1 receptor-mediated changes in
the intracellular Ca21 concentration and subsequent NAPE-PLD-
mediated anandamide synthesis as well as FAAH-mediated ananda-
mide hydrolysis, is considered to be prominently suitable to provide a
significant control over TRPV1 and CB1 receptor activity in and, hence,
over the excitation of a major group of nociceptive primary sensory
neurons (Sousa-Valente, Varga, Ananthan, K., Khajuria, A., & Nagy, I.
2014; van der Stelt & Di Marzo, 2005; Varga et al., 2014).
The excitation level of nociceptive primary sensory neurons is piv-
otal for the initiation and maintenance of pain experiences, including
those that are associated with peripheral pathologies, such as inflam-
mation of peripheral tissues and injury to peripheral nerves (Nagy, San-
tha, Jancso, & Urban, 2004; Sousa-Valente, Andreou, Urban, & Nagy,
2014). Therefore, the control provided by the endocannabinoid/endo-
vanilloid autocrine signaling system built by the CB1 receptor, TRPV1,
NAPE-PLD, and FAAH in a major group of nociceptive primary sensory
neurons might play an important role in the development and mainte-
nance of pain. Although the expression patterns and the changes in
those expression patterns by pathological conditions of the CB1 recep-
tor, TRPV1, and FAAH have been comprehensively elucidated (Amaya
et al., 2004, 2006; Bar, Schaible, Brauer, Halbhuber, & von Banchet,
2004; Hudson et al., 2001; Ji, Samad, Jin, Schmoll, & Woolf, 2002;
Lever et al., 2009; Luo, Cheng, Han, & Wan, 2004; Malek et al., 2015;
Mitrirattanakul et al., 2006; Yu et al., 2008; Zhou, Li, & Zhao, 2003), lit-
tle is known about those properties and changes of NAPE-PLD. There-
fore, to improve our understanding of the putative autocrine
cannabinoid/endovanilloid signaling in primary sensory neurons, this
article describes the coexpression patterns of NAPE-PLD with TRPV1,
the CB1 receptor, and FAAH under naive conditions and changes in
those expression patters under pathological conditions. Preliminary
findings were reported earlier by Valente et al. (2011).
2 | METHODS AND MATERIALS
Forty-two male Wistar rats (250–300g) and 10 C57BL/6 wild-type
(WT) and 10 NAPE-PLD–/– (Leung, Saghatelian, Simon, & Cravatt,
2006; Tsuboi et al., 2011) adult mice were used in this study. NAPE-
PLD–/– mice were generated by the deletion of a sequence (from
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amino acids 99–313) that contains the catalytic domain of the enzyme
(Leung et al., 2006; Tsuboi et al., 2011). Both WT and NAPE-PLD–/–
mice have been used for antibody control purposes. All quantitative
assessments on NAPE-PLD expression pattern have been performed
on rat tissues.
All procedures were performed according to the United Kingdom
Animals (Scientific Procedures) Act 1986, the revised National Insti-
tutes of Health Guide for the care and use of laboratory animals, the
Directive 2010/63/EU of the European Parliament and of the Council
on the Protection of Animals Used for Scientific Purposes, and the
guidelines of the committee for research and ethical issues of IASP
(Zimmerman, 1983). Furthermore, we fully followed good laboratory
practice and ARRIVE guidelines, and every effort was taken to mini-
mize the number of animals used.
2.1 | Rat models of inflammatory and neuropathic
pain
Tissue inflammation was induced by injecting 50ml of 50% complete
Freund’s adjuvant (CFA; Thermo Scientific, Billerica, MA) or incomplete
Freund’s adjuvant (IFA; Thermo Scientific) subcutaneously into the
plantar aspect of the left hind paw of adult rats. The injection was per-
formed under isoflurane-induced anesthesia.
Nerve injury was produced according to previously published pro-
tocols (Kim & Chung, 1992). Briefly, rats were deeply anesthetized
with isoflurane, and the fifth lumbar (L5) spinal nerve was exposed and
identified after partial laminectomy. A tight 4.0 ligature was then
placed around the nerve. The nerve was cut about 5mm distal from
the ligature, and the wound was closed in layers. The sham operation
consisted of exposing the L5 spinal nerve without placing the ligature
or cutting the nerve.
2.2 | Testing pain-related behavior
Inflammation- or nerve injury-induced changes in responses to
mechanical stimuli were assessed with an electrical von Frey apparatus
(Ugo Basile, Gemonio, Italy). Briefly, rats were placed in a Perspex
chamber with a 0.8-cm-diameter mesh flooring and allowed to acclima-
tize for 15min. The tip of the probe was pressed against the plantar
surface of the paw at a steadily increasing pressure until the animal vol-
untarily withdrew the paw. The paw-withdrawal threshold was defined
as the average weight in grams over three applications. Care was given
not to repeat testing on the same paw within 5min. Responses to
mechanical stimuli were assessed every day for 2 days prior to and 3
days after the injection of either CFA or IFA. In animals that were sub-
jected to nerve injury, changes in the sensitivity to mechanical stimula-
tion were assessed every day for 2 days prior to the surgery and then
on the second, fourth, and seventh days after the surgery.
Inflammation- or nerve injury-induced changes in responses to
noxious heat stimuli were assessed by the Hargreaves test (Hargreaves,
Dubner, Brown, Flores, & Joris, 1988). Briefly, rats were placed in a
Perspex box. After a 15-min acclimatization period, an infrared beam
(Ugo Basile), which is able to deliver a constantly increasing thermal
stimulus, was directed to the plantar surface of the paw. The time until
the animal voluntarily withdrew the paw was measured. Again, atten-
tion was given not to repeat testing on the same paw within 10min.
Responses to heat and mechanical stimuli were assessed on the same
days.
2.3 | Reverse transcription polymerase chain reaction
Rats were killed with isoflurane, and L4 and L5 dorsal root ganglia
(DRG) were collected in RNAlater (Sigma-Aldrich, St. Louis, MO) and
homogenized with QIA shredder columns (Qiagen, Manchester, United
Kingdom). Total RNA was extracted with an RNeasy Plus Mini kit
(Qiagen) according to the manufacturer’s instruction. RNA was
reverse-transcribed with SuperScript II cDNA synthesis reagents
(Invitrogen, Carlsbad, CA). Sequences of the primers (Eurofins MWG
Operon, Regensburg, Germany) designed to amplify rat NAPE-PLD
(NM_199381.1) are forward: TACCAACATGCTGACCCAGA; reverse:
ATCGTGACTCTCCGTGCTTC. Sequences of primers designed to
amplify the housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH; NC_005103) are forward: ACCCATCACCATCTTCCA;
reverse, CATCACGCCACAGCTTTCC. The annealing temperature was
578C; product sizes were 199 bp for NAPE-PLD and 380 bp for
GAPDH. The polymerase chain reaction (PCR) mixture was composed
of cDNA, primers, 1.5mM MgCl2, 13Green Go-Taq reaction buffer
(Promega, Madison, WI), 0.2mM deoxynucleotide mix (Promega), and
1.25 U Go-Taq DNA polymerase (Promega); the number of cycles was
30. After amplification, PCR products were separated by electrophore-
sis on 2% agarose gels and visualized with ethidium bromide in Syn-
gene G:Box (Synoptics, Cambridge, United Kingdom). Images were
analyzed in Syngene’s GeneTools software (Synoptics).
2.4 | Western blotting
Rats and mice were killed with isoflurane, and L4 and L5 DRG were
collected and homogenized on ice in NP40 cell lysis buffer (Invitrogen)
supplemented with a protease inhibitor cocktail (Sigma-Aldrich). The
protein content of the samples was determined with the BCA protein
assay reagent (Pierce Biotechnology, Rockford, IL). Proteins were dena-
tured at 958C for 10min with 43 concentrated NuPAGE LDS sample
buffer (Invitrogen), after which they were run in a NuPAGE Novex 4–
12% Bis-Tris gel (Invitrogen) and blotted onto a PVDF membrane with
the iBlot dry blotting system (Invitrogen). To visualize NAPE-PLD, the
membrane was first incubated in 5% nonfat milk and then in an anti-
NAPE-PLD antibody (1:1,000; Aviva Systems Biology, San Diego, CA)
overnight at 48C. The anti-NAPE-PLD antibody has been raised against
the 71–130-amino-acid sequence of the protein (TWKNPSIPNVLRWLI
MEKDHSSVPSS KEELDKELPVLKPYFITNPEEAGV). Forty-four percent
of this sequence is missing in NAPE-PLD–/– mice (Leung et al., 2006;
Tsuboi et al., 2011).
After the membranes had been incubated in the anti-NAPE-PLD
antibody, they were incubated with horseradish peroxidase-conjugated
goat anti-rabbit secondary antibody (1:1,000; Cell Signaling Technology,
Danvers, MA) for 1hr at room temperature. Western blotting luminol
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reagent (Santa Cruz Biotechnology, Santa Cruz, CA) was used for visual-
ization. Images were captured in Syngene G:Box and analyzed in Syn-
gene’s GeneTools software. Membranes were then stripped with 0.2M
glycine stripping buffer supplemented with 0.5% Tween-20 (pH3.0) at
room temperature for 30min and reprobed with rabbit anti-b-actin as a
loading control (1:1,000; Cell Signaling Technology).
2.5 | Immunostaining
Animals were killed by intraperitoneal injection of sodium pentobarbital
(60mg/kg) and perfused through the ascending aorta with 100ml of
0.9% saline, followed by 300ml of 4% paraformaldehyde in 0.1M
phosphate buffer (PB; pH7.4). The cerebellum and L4 and L5 DRG
were identified and collected bilaterally. Tissues were postfixed for 4–
24hr at 48C in 4% paraformaldehyde in 0.1M PB, cryoprotected in
30% sucrose in 0.1M PB for 1–2 days at 48C, embedded in a mounting
medium, and cut with a cryostat into sections of 10mm for DRG tissue
or 30mm for cerebella that were mounted on Superfrost slides.
Slides were washed with PBS containing 0.3% Triton X-100
(PBST) and then incubated with PBST containing 10% normal donkey
serum (Jackson Immunoresearch, West Grove, PA) for 1 hr at room
temperature. Slides were then incubated for 24hr at room temperature
in PBST containing 2% NDS and the appropriate primary antibody/
antibodies. In addition to the anti-NAPE-PLD antibody described
above, the antibodies included anti-NF200 (200-kD neurofilament)
antibody (Sigma-Aldrich) clone NE14, anti-calcitonin gene-related pep-
tide (CGRP) antibody (AB22560; Abcam, Cambridge, MA), anti-TRPV1
antibody (A. Avelino laboratory) EDAEVFKDSMVPGEK, anti-CB1
receptor antibody (K. Mackie laboratory) SCNTATCVTHR-
LAGLLSRSGGVVKDNFVPTNVGSEAF, and anti-FAAH antibody (B.
Cravatt laboratory) GAATRARQKQRASLETMDKAVQRFRLQNPDLDS
EALLTLPLLQLVQKLQSGELSPEAVFFTYLG KAWEVNKGTNCVTSYLTD
CETQLSQAPRQGLLYGVPVSLKECFSYKGHDSTLGLSLNEGMPSESDC
VVVQVLKLQGAVPFVHTNVPQSMLSFDCSNPLFGQTMNPWKSSKSP
GGSSGGEGALIGSGGSPLGLGTDIGGSIRFPSAFCGICGLKPTGNRLSKS
GLKGCVYGQTAVQLSLGP MARDVESLALCLKALLCEHLFTLDPTVPPL
PFREEVYRSSRPLRVGYYETDNYTMPSPAMRRALIE TKQRLEAAGHT-
LIPFLPNNIPYALEVLSAGGLF SDGGRSFLQNFKGDFVDPCLGDLILILR
LPSWF KRLLSLLLKPLFPRLAAFLNSMRPRSAEKLWKL QHEIEMYRQS
VIAQWKAMNLDVLLTPMLGPALD LNTPGRATGAISYTVLYNCLDFPA
GVVPVTTVTAEDDAQMELYKGYFGDIWDIILKKAMKNSVGL PVAVQ
CVALPWQEELCLRF MREVEQLMTPQKQPS. In most of the experi-
ments, NAPE-PLD immunostaining was amplified by the tyramide sig-
nal amplification (TSA) system (Perkin Elmer Life Sciences, Waltham,
MA) instructions. Immunostaining was visualized by 488-nm or 568-
nm Alexa Fluor-conjugated streptavidin (1:1,000; Invitrogen) or a
fluorophore-conjugated secondary antibody for 1 hr. Previously, we
had extensively tested the specificity and selectivity of the anti-
TRPV1, anti-CB1, and anti-FAAH antibodies (Cruz et al., 2008; Lever
et al., 2009; Veress et al., 2013).
For the TSA amplification, after incubation of sections in the pri-
mary antibody, a biotinylated secondary antibody (1:500 biotin donkey
anti-rabbit; Jackson Immunoresearch) was applied. Slides were then
incubated with peroxidase containing avidin–biotin complex (1:200;
ABC kit; Perkin Elmer Life Sciences) for 1 hr. The biotinylated tyramide
was detected with fluorescent streptavidin (see above). To control for
the combined use of two antibodies raised in the same species in com-
bination with the TSA amplification, the following experiments were
conducted: (a) the primary antibody was omitted; (b) a fluorescent sec-
ondary antibody recognizing the species in which the primary antibody
had been produced was added at the end of the TSA reaction to deter-
mine whether any unoccupied primary antibody could generate signal;
and (c) for the same primary antibody, a TSA reaction and primary fluo-
rescent secondary antibody reaction were performed in tandem in
adjacent sections to verify whether both types of reactions would yield
similar results.
In addition to the antibodies, fluorescein-labeled Griffonia simplici-
folia isolectin B4 (IB4; Sigma-Aldrich) was used to identify the nonpep-
tidergic subpopulation of nociceptive primary sensory neurons
(Silverman & Kruger, 1990). This was performed by incubating sections
in a 1:1,000 dilution of the fluorochrome-conjugated IB4 for 1hr dur-
ing the final incubation step for NAPE-PLD staining. Slides were
mounted in Vectashield medium (Vector Laboratories, Burlingame, CA).
2.6 | Control experiments
For testing the specificity and selectivity of the anti-NAPE-PLD anti-
body, we first studied proteins identified by the anti-NAPE-PLD anti-
body in protein samples prepared from the cerebella of WT and NAPE-
PLD–/– mice. Furthermore, we studied the immunostaining generated
by the anti-NAPE-PLD antibody in sections that had been cut from
DRG and cerebellum of WT and NAPE-PLD–/– mice. Finally, we stud-
ied the proportion and size distribution of cells expressing NAPE-PLD
mRNA as well as the coexpression pattern between NAPE-PLD mRNA
and NAPE-PLD protein (vide infra).
2.7 | Fluorescent in situ hybridization
Fluorescent in situ hybridization was carried out with a custom Stellaris
FISH probe kit, which contains 48 fluorescent dye-conjugated NAPE-
PLD mRNA complementary short probes (Biosearch Technologies, Pet-
aluma, CA). All material and stock solutions were treated with diethyl
pyrocarbonate (DEPC; Sigma-Aldrich) or RNase ZAP (Sigma-Aldrich) or
kept at –808C for 8hr to prevent RNA degradation. The DEPC treat-
ment included adding 2.5mM DEPC to all solutions and autoclaving.
DRG sections mounted on coverslips were washed with PBS and then
permeabilized with 70% ethanol for 1hr at room temperature. After
having been rinsed in washing buffer that contained 20% formamide
and 23 concentrated saline sodium citrate (SSC) buffer that contained
sodium chloride and trisodium citrate, slides were incubated with the
NAPE-PLD probe (2.5mM) in hybridization buffer (23SSC buffer, 10%
formamide, and 100mg/ml dextran sulfate) at room temperature for
24hr. On the next day, after a 1-hr incubation in the washing buffer,
slides were immunoreacted with the NAPE-PLD antibody as described
above. For control, sections were incubated as described above, but
the NAPE-PLD probes were omitted from the hybridization buffer.
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Control sections were run in parallel with sections incubated in the
presence of the NAPE-PLD probes.
2.8 | Image analysis and quantification of
immunofluorescent DRG cells
Immunofluorescent images were examined with a Leica (Wetzlar, Ger-
many) DMR Fluorescence, Zeiss (Jena, Germany) Axioscope 40, or
Zeiss LSM 700 confocal laser scanning microscope. With the Leica
microscope, images were taken by a Hamamatsu CCD camera con-
nected to a PC running QWIN software (Leica). The PC connected to
the Zeiss Axioscope 40 ran AxioVision 4.6, whereas the PC connected
to the Zeiss LSM 700 microscope ran ZEN software.
With each microscope, corresponding identical acquisition parame-
ters were used and raw, unprocessed images were used for analysis in
Image J. Images selected for figures, however, were subjected to con-
trast and brightness adjustments when we determined that was
required.
Neurons that displayed a visible nucleus were identified, and the
cytoplasm and the nuclei of these cells were marked as regions of
interest (ROI). The area and mean pixel intensity of the ROIs were then
measured. At least 200 cells were sampled in each side of each animal
in serial sections at a distance of 610 sections (i.e., 100lm) apart from
one another to ensure that each cell with a given staining was included
in the analysis only once.
The threshold staining intensity was established by using three
independent methods. First, with visual inspections, we confirmed that
sections contained both immunopositive and immunonegative cells.
The presence of the two types of neurons was also confirmed by the
non normal distribution of the staining intensities in each section (Sha-
piro-Wilk test). k-Clustering is able to separate variables into a defined
number of clusters that then exhibit the greatest possible distinction.
Therefore, we used k-clustering to define two clusters and the intensity
values that separate the two groups of neurons in each section.
In the second method, raw intensity values were transformed by
using a logarithmic equation (LOG[255/(255—value)]). These values
were ranked and displayed on a scatterplot. The initial and last linear
parts of the plots were then fitted with a tangent, and the intensity
value at the intersection of the two fitted lines was used as a threshold
to separate labeled and nonlabeled cells. This initial separation was
then used in a discriminant analysis as prediction. This statistical probe
also confirmed that the accuracy of the prediction was between 95%
and 100%.
Finally, one blinded experimenter examined images of randomly
chosen sections from naive animals, and the immunopositivity or
immunonegativity judged by that experimenter was noted; these notes
were then associated with the staining intensity values measured in
ImageJ. These combined data were then used to determine the thresh-
old of immunopositivity by the receiver operating curve. The ratio of
immunopositive and immunonegative cells determined by the three
methods did not differ more than 5%. Data presented throughout the
article were obtained with the second method.
In addition to establishing the immunopositive and immunonega-
tive cells, intensity values were also used for studying pathology-
induced changes in staining intensities of NAPE-PLD, TRPV1, CB1
receptor, and FAAH immunopositivity as well as pathology-induced
changes in the correlation between staining intensities of NAPE-PLD
and TRPV1, CB1 receptor, or FAAH immunopositivity.
2.9 | Statistical analysis
For naive animals, data from both the left and the right sides were ana-
lyzed and used for further statistical analysis. For treated animals, data
obtained from the ipsilateral and the contralateral sides of the same
treatment group were averaged, tested for normal distribution (Sha-
piro–Wilk test), and analyzed for statistical differences. Statistical ana-
lysis of behavioral data was performed between withdrawal responses
(on different testing days or among different animal groups on the
same testing day) by ANOVA, followed by Tukey’s test or by two-
tailed Student’s t test, as appropriate. Statistical comparisons among
the number of immunostained cells identified in different experimental
groups were performed by two-tailed Fisher’s exact test. Differences
among sizes of neurons belonging to various populations were com-
pared by two-tailed Mann-Whitney U test. All data are expressed as
mean6 SEM; “n” refers to the number of repeated measurements in
each of the experimental groups. p< .05 was considered to be statisti-
cally significant.
3 | RESULTS
3.1 | NAPE-PLD is expressed in primary sensory
neurons of DRG
Gel images of RT-PCR products exhibited detectable levels of NAPE-
PLD mRNA in L4–5 rat DRG (Figure 1a). The size of the PCR product
was indistinguishable from the expected product size of 199 bp (Figure
1a). These findings support previous data showing that a subpopulation
of primary sensory neurons expresses NAPE-PLD (Bishay et al., 2010;
Nagy et al., 2009).
To confirm that NAPE-PLD mRNA is expressed in neurons in
DRG, we performed fluorescent in situ hybridization in sections cut
from rat L4–5 DRG. Analysis of the staining confirmed that NAPE-PLD
mRNA is expressed in DRG and that only a subpopulation of neurons
expresses this transcript (Figure 1b,c).
To determine whether NAPE-PLD protein is also expressed in rat
DRG, we performed Western blotting. The anti-NAPE-PLD antibody
(Aviva Systems Biology) we used throughout this study recognized, in
addition to some unknown proteins, a protein with the predicted size
of NAPE-PLD (46 kDa) in samples prepared from rat DRG (Figure
2a). In addition, the anti-NAPE-PLD antibody also recognized a protein
with the predicted size (46 kDa) in WT mouse brain (together with,
apparently, the same unknown proteins; Figure 2a). However, although
the antibody recognized the unknown proteins, it did not recognize the
specific 46-kDa protein in samples prepared from the brains of
NAPE-PLD–/– mice (Figure 2a).
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To confirm that the NAPE-PLD protein is expressed exclusively by
neurons in DRG, we incubated sections cut from rat L4–5 DRG with
the anti-NAPE-PLD antibody and visualized the staining via TSA. Anal-
ysis of the immunostaining revealed that the antibody produced a
homogenous staining in the cytoplasm of DRG neurons (Figure 2b). In
addition to DRG neurons, a fluorescent signal was also seen in some
satellite cells (Figure 2b). However, our control experiments revealed
that this staining is produced by the TSA reaction when the postfixa-
tion time is less than 24hr (data not shown).
To obtain evidence that the anti-NAPE-PLD antibody produces a
selective and specific immunostaining, we immunoreacted cerebellum
and DRG sections of WT and NAPE-PLD–/– mice (Figure 3a–d). As
expected (Nagy et al., 2009; Suarez et al., 2008), WT mouse Purkinje
cells (Figure 3a1–4) as well as a subpopulation of WT mouse DRG neu-
rons (Figure 3c1–4) exhibited strong NAPE-PLD immunoreactivity. In
contrast, the immunoreaction produced by this antibody was lost in
both cerebella and DRG dissected from NAPE-PLD–/– mice (Figure
3b1-4,d1-4).
To provide additional evidence that the anti-NAPE-PLD antibody
produces a specific and selective staining, we also combined the immu-
nostaining with in situ hybridization using fluorescent NAPE-PLD
probes (Figure 4). Analysis of this combined staining revealed that 73
of 231 cells (31.6%) showed positivity for the in situ probes. The num-
ber of cells showing NAPE-PLD immunopositivity was not significantly
different from this value (75 of 231 [32.5%], p5 .9, Fischer’s exact
test). The proportion of immunopositive neurons was not significantly
different from that found in naive animals in the remainder of the study
(37.6%60.17%, n518, p5 .13, Fischer’s exact test). The combined
fluorescent in situ hybridization and immunofluorescent staining also
revealed that 59 of the total number of neurons showed double stain-
ing (25.6%), which represented 80.8% and 78.7% of the in situ- and
immunopositive cells, respectively.
FIGURE 2 The NAPE-PLD protein is expressed in adult rat DRG.
(a) A gel image (top) of immunoblots with an antibody raised
against NAPE-PLD and protein samples prepared from rat DRG (R/
DRG), NAPE-PLD–/– mouse brain (KO/BR), or WT mouse brain
(WT/BR). In addition to recognizing a protein with the predicted
size of NAPE-PLD (46 kD) in rat DRG and WT mouse brain tis-
sues, the antibody also recognized some unknown proteins in all
samples. However, the antibody failed to recognize the protein
with the predicted size of NAPE-PLD in NAPE-PLD–/– mouse brain.
Bottom image shows b-actin (42 kD) expression as loading control.
(b) Microphotograph of a section cut from a rat DRG. The anti-
NAPE-PLD antibody produced staining in a subpopulation of pri-
mary sensory neurons (arrowheads). In addition, satellite cells visi-
ble occasionally around primary sensory neurons also exhibit
NAPE-PLD immunopositivity (arrows). However, control experi-
ments revealed that this staining is produced by the TSA reaction
when the postfixation time is less than 24 hr. Scale bar530 mm
FIGURE 1 The NAPE-PLD transcript is expressed in adult rat
DRG. (a) Gel image of RT-PCR products that were synthesized
from total RNA isolated from the L4–5 DRG of adult rats with pri-
mers designed to amplify NAPE-PLD (N, top) and GAPDH (G, bot-
tom) mRNA. The size of the RT-PCR products is indistinguishable
from the predicted size of NAPE-PLD (N, 199 bp) and GAPDH (G,
380 bp). (b) Microphotograph taken from a DRG section of an adult
rat following fluorescent in situ hybridization with 48 short NAPE-
PLD complementary fluorescent dye-tagged probes. The labeling
identified only neurons (arrowheads). The great majority of the
positive neurons were small-diameter cells. (c) Microphotograph
taken from another rat DRG section that was incubated in parallel
with the one shown in B in identical solutions with the exception
that the specific in situ probes were omitted from the hybridization
buffer. Scale bars520 lm in both (b) and (c)
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3.2 | NAPE-PLD is expressed in small DRG neurons
Next, we analyzed the morphology and neurochemical properties of
NAPE-PLD-expressing primary sensory neurons. Among the 8,129
DRG neurons that we analyzed, 3,056 were NAPE-PLD immunoreac-
tive (37.60%60.17%, ipsilateral and contralateral sides of nine animals,
n518 repeated measurements; Table 1). The cell size distribution of
FIGURE 3.
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NAPE-PLD-immunostained neurons revealed that most of the NAPE-
PLD-expressing cells were small neurons, although some large NAPE-
PLD-immunopositive cells were also found (Figure 5). The area of peri-
karya of the NAPE-PLD-immunoreactive cells was 92369mm2
(n53,056). This value was significantly smaller than the average area
of perikarya of unlabeled cells (1,315610mm2, n55,073, p5 .01,
two-tailed Mann Whitney U test).
3.3 | NAPE-PLD is expressed by both peptidergic and
nonpeptidergic nociceptive neurons
The great majority of small-diameter primary sensory neurons are noci-
ceptive in function (Nagy, Santha, Jancso, & Urban, 2004). Although
nociceptive primary sensory neurons either contain neuropeptides
such as CGRP or express the binding site for the lectin IB4, non noci-
ceptive neurons express the heavy (200 kDa) neurofilament NF200
(Lawson, Harper, Harper, Garson, & Anderton, 1984; Lawson & Wad-
dell, 1991). Therefore, to confirm that NAPE-PLD-expressing DRG
neurons are indeed nociceptive, we used combined immunofluorescent
staining with the anti-NAPE-PLD antibody (an anti-NF200) and an
anti-CGRP antibody as well as fluorescein-conjugated IB4 on sections
cut from L4–5 DRG. The results of these combined immunoreactions
are shown in Figure 6 and Table 1. In summary, 31.28%63.89%
(n56) of the NAPE-PLD immunoreactive neurons expressed NF200
(154 of 502 cells in the left and right sides of three animals; Figure 6a–
c, Table 1). In contrast, 52.05%62.02% (n56) of the cells bound IB4
(267 of 512 cells in the left and right sides of three animals; Figure 6d–
f, Table 1), and 34.58%62.67% (n56) of the cells exhibited immuno-
positivity for the neuropeptide CGRP (174 of 509 cells in the left and
right sides of three animals; Figure 6g–i, Table 1). It is important to
note that more NAPE-PLD-expressing cells bound IB4 than contained
CGRP (p< .001, Fisher’s exact test).
3.4 | NAPE-PLD shows a high level of coexpression
with TRPV1, the CB1 receptor, and FAAH
To discover whether NAPE-PLD could indeed be involved in the for-
mation of an autocrine endocannabinoid/endovanilloid signaling sys-
tem in a subpopulation of primary sensory neurons, we next assessed
the coexpression of NAPE-PLD and FAAH, the CB1 receptor, or
TRPV1. Data from the analysis of these combined immunoreactions
are shown in Figure 7 and Table 1. In summary, we found a very high
level of coexpression between NAPE-PLD and all the endocannabi-
noid/endovanilloid signaling-related molecules (Figure 7, Table 1).
However, significantly more (p5 .029, Fisher’s exact test) NAPE-PLD-
immunopositive neurons expressed the CB1 receptor (72.71%6
1.47%, n56, 349 of 480 cells in three animals) than TRPV1
(59.89%61.33%, n56,304 of 546 cells in the left and right sides of
three animals).
We also assessed the correlation between the intensities of
NAPE-PLD and the CB1 receptor, TRPV1, or FAAH immunostaining.
Although NAPE-PLD and CB1 receptor immunostaining exhibited a
high correlation (R5 .766 .02, n53; Figure 8a), essentially no correla-
tion was found between NAPE-PLD and TRPV1 immunostaining
(R5 .146 .07, n53; Figure 8b). Furthermore, a weak correlation
(R5 .346 .06, n53; data not shown) was found between the inten-
sities of NAPE-PLD and FAAH immunoreactivity.
3.5 | Both CFA and IFA injection induce changes in
NAPE-PLD, TRPV1, and the CB1 receptor
immunolabeling pattern
In primary sensory neurons, one of the main functions of anandamide’s
excitatory target, TRPV1, is to signal peripheral inflammatory events to
the central nervous system (Nagy, Friston, Valente, Perez, & Andreou,
2014; White, Urban, & Nagy, 2011). To determine whether peripheral
inflammation induces changes in NAPE-PLD expression that may be
associated with increased TRPV1 activity, after the assessment of
behavioral changes, we studied the expression pattern of NAPE-PLD,
TRPV1, the CB1 receptor, and FAAH after the induction of inflamma-
tion in the hind paw.
CFA injection into the hind paw produced hypersensitivity to both
thermal and mechanical stimuli 3 days after injection, which was signifi-
cantly greater than that induced by IFA (data not shown). The propor-
tion of NAPE-PLD immunostained neurons was significantly reduced
by both CFA and IFA injections on the ipsilateral side (from 37.60%6
0.17% [3,056/8,129 cells in the left and right sides of nine animals],
n518, to 35.18%60.64% [1,363/3,872 in the ipsilateral side of three
animals], p5 .01, Fisher’s exact test, by IFA and to 35.40%60.60%
FIGURE 3 The NAPE-PLD antibody provides specific and selective staining. (a1–4) Microphotographs (taken with the Zeiss Axiotome
microscope) of a section cut from a WT mouse (NAPE-PLD1/1) cerebellum and immunostained with the combination of an anti-NAPE-PLD
(a1, green) and an anti-b-III tubulin (a2, red) antibody. The section was also stained with DAPI (a3, blue). (a4) shows a composite image of
(a1–3). Consistent with previous findings, the perikarya of Purkinje cells show strong immunopositivity for NAPE-PLD (arrowheads). (b1–4)
Microphotographs (taken with the Zeiss Axiotome microscope) of a section cut from the cerebellum of a NAPE-PLD–/– mouse and immu-
noreacted with the mixture of the anti-NAPE-PLD (b1) and the anti-b-III tubulin (b2) antibodies. The section was also stained by DAPI (b3).
(b4) shows a composite image of (b1–3). Note the complete lack of immunolabeling by the anti-NAPE-PLD antibody. (c1–4) Microphotographs
(taken with the Zeiss Axiotome microscope) of a section cut from a WT mouse DRG and immunostained with the mixture of the anti-
NAPE-PLD (c1) and the anti-b-III tubulin (c2) antibodies. The section was also stained by DAPI (c3). (c4) shows a composite image of (c1–3).
The immunoreaction produced staining in a subpopulation of neurons (arrowheads). (d1–4) Microphotographs (taken with the Zeiss Axio-
tome microscope) of a section cut from a NAPE-PLD–/– mouse DRG and immunostained with the mixture of the anti-NAPE-PLD (d1) and
the anti-b-III tubulin (d2) antibodies. The section was also stained by DAPI (d3). (d4) shows a composite image of (d1–3). Note the complete
lack of NAPE-PLD immunopositivity. Images of DRG sections are stack images from eight images of 1.25 lm each. Images of the cerebellum
are stack images from 12 images of 1.42 lm each. Scale bars550 mm
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[1,483/4,181 cells in the ipsilateral side of three animals], p5 .02, Fish-
er’s exact test, by CFA; Figure 9, Table 2) but not on the contralateral
side. The cell size distribution of the NAPE-PLD-immunopositive cells
was not changed on either the ipsilateral side or the contralateral side
(data not shown). The high correlation between NAPE-PLD and CB1
receptor immunostaining intensity was significantly reduced by both
CFA injection (from 0.7660.02 [n53] to 0.4860.03 [n53],
p< .001, Student’s t-test; Figure 8c) and by IFA injection (from 0.766
0.02 [n53] to 0.5760.02 [n53], p< .001, Student’s t-test; data not
shown) on the ipsilateral side but not on the contralateral side. Further-
more, the ipsilateral/contralateral ratios of NAPE-PLD, CB1 receptor,
and FAAH immunostaining were not changed (Figure 8d). However,
the ipsilateral/contralateral ratio for TRPV1 immunolabeling was
increased by both IFA injection (from 160.03 [n53] in naive to
1.2160.07 [n53] in IFA-injected animals, p5 .02, Student’s t test;
data not shown) and CFA injection (from 160.03 [n53] in naive to
1.1660.05 [n53] in CFA-injected animals, p5 .03, Student’s t test;
Figure 8d).
3.6 | Spinal nerve ligation results in a pronounced
reduction of NAPE-PLD immunoreactivity in injured
DRG neurons
Nerve injury has been associated with changes in expression in many
proteins, including various components of the endocannabinoid/endo-
vanilloid systems and in anandamide levels in DRG (Agarwal et al.,
TABLE 1 Summary of the proportion of neurons expressing NAPE-PLD and other markers in L4–5 DRG of naive animals
Number of cells
used for analysis
Percentage of
neurons expressing
various markers
Percentage of
NAPE-PLD-expressing cells
expressing various markers
Percentage of neurons expressing
various markers together
with NAPE-PLD
NAPE-PLD 8,129 386 0.3 - -
NF200 1,313 376 0.5 316 3.9 326 3.3
IB4 1,361 346 0.6 526 2.0 576 2.1
CGRP 1,374 386 0.5 356 2.7 346 2.8
TRPV1 1,350 426 0.7 606 1.3 546 2.3
CB1 1,267 346 0.6 736 1.5 826 1.6
FAAH 1,464 346 1.2 626 2.8 676 3.3
FIGURE 4 Combined staining with NAPE-PLD in situ probes and the anti-NAPE-PLD antibody reveals a high degree of costaining. (a)
Microphotograph shows the result of fluorescent in situ hybridization in a rat DRG section with fluorescent dye-tagged probes specific for
NAPE-PLD mRNA. Labeling identified a group of neurons (arrowheads). (b) Microphotograph shows the image of the same cells shown in A
immunolabeled with the anti-NAPE-PLD antibody. Arrowheads indicate NAPE-PLD-immunopositive cells. (c) Microphotograph of the visual
field shown in A and B but stained with DAPI. (d) Composite image of A–C. Arrowheads indicate double-labeled cells. In this visual filed,
the costaining of neurons is 100%. Scale bar520 mm
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2007; Costigan et al., 2002; Hudson et al., 2001; Lever et al., 2009;
Michael & Priestley, 1999; Zhang, Zhao, Jiang, Wang, & Ma, 2007).
Therefore, we next assessed nerve injury-induced alterations in NAPE-
PLD, FAAH, TRPV1 and CB1 receptor expression.
In agreement with previous results (Kim & Chung, 1992), ligation
and transection of the fifth lumbar spinal nerve but not sham surgery
resulted in the development of reflex hypersensitivity to mechanical
and thermal stimuli from 2 to 7 days after the surgery (data not shown).
Both the nerve injury and the sham surgery resulted in significant
reductions in the number of NAPE-PLD-immunostained neurons in the
injured DRG (from 37.60%60.17% [3,056 of 8,129 cells in the left
and right sides of nine animals, n518] to 33.71%62.19% [653 of
1,932 cells in three sets of samples, that is, three different combined
stainings from the ipsilateral side of three animals, n59, p5 .002,
FIGURE 6 Most primary sensory neurons expressing NAPE-PLD also express markers for nociceptive primary sensory neurons. Combined
immunolabeling was produced by using the anti-NAPE-PLD antibody with an antibody raised against the 200-kD neurofilament NF200 (a–
c), with biotinylated IB4 (d–f), or with an antibody raised against CGRP (g–i). (a–c) show a typical combined image (a) and separated images
(b,c) of a section incubated with the anti-NAPE-PLD (b, green) and an anti-NF200 (c, red) antibody. NAPE-PLD shows a low degree of coex-
pression with NF200. (d–f) show a typical combined image (d) and separated images (e,f) of a section incubated with the anti-NAPE-PLD
antibody (e, green) and a biotinylated IB4 (red; f). NAPE-PLD shows a high degree of coexpression with the IB4 binding site. (g–i) show a
typical combined image (g) and separated images (h,i) of a section incubated with the anti-NAPE-PLD (h, green) and anti-CGRP antibody (i,
red). NAPE-PLD also shows coexpression with CGRP. Arrowheads in (d) and (g) indicate NAPE-PLD/IB4-binding site-expressing neurons
and NAPE-PLD/CGRP-immunopositive neurons, respectively. For quantified data, see Table 1. All images are single scan images acquired
with a 320 objective lens (NA: 0.50) and a 47-mm pinhole aperture corresponding to 1.29 Airy units, providing four 6-mm-thin optical sec-
tions. Scale bar550 mm
FIGURE 5 Most primary sensory neurons expressing NAPE-PLD
are small cells. Cell size distribution of NAPE-PLD-immunopositive
(green bars) and -immunonegative (gray bars) rat DRG neurons.
The great majority of the NAPE-PLD-immunopositive cells are
small cells, although some larger cells also express NAPE-PLD
[Color figure can be viewed at wileyonlinelibrary.com]
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Fischer’s exact test by sham surgery] and to 18.50%61.42% [653 of
1,932 cells in three sets of samples from the ipsilateral side of three
animals, n59, p< .001, Fischer’s exact test by spinal nerve ligation
(SNL)]; Figure 10, Table 3), although the SNL-induced reduction was
significantly greater than that produced by the sham injury (p< .001,
Fischer’s exact test). SNL but not the sham injury also reduced the
number of TRPV1-immunolabeled neurons (from 42.14%60.69%
[569 of 1,350 cells in the ipsilateral and contralateral sides of three ani-
mals, n56] to 6.38%66.15% [41 of 695 cells in the ipsilateral side of
three animals, n53], p< .001, Fischer’s exact test) and CB1 receptor-
immunolabeled neurons (from 33.64%60.59% [426 of 1,267 cells in
the ipsilateral and contralateral sides of three animals, n56] to
24.64%68.46% [96 of 653 cells in the ipsilateral side of three animals,
n53], p< .001, Fischer’s exact test) and increased the number of
FAAH-immunolabeled neurons (from 34.39%61.24% [501 of 1,464
cells in the ipsilateral and contralateral sides of three animals, n56] to
50.81%66.49% [307 of 614 cells in the ipsilateral side of three ani-
mals, n53], p< .001, Fischer’s exact test) in the injured DRG (Figure
10, Table 3). Both the sham injury (data not shown) and the SNL signifi-
cantly reduced the correlation between the intensities of NAPE-PLD
and CB1 receptor immunolabeling on both the ipsilateral (Figure 8c)
and the contralateral (data not shown) sides. Although the number of
TRPV1-immunopositive cells was reduced, the ipsilateral/contralateral
ratio of TRPV1 immunolabeling was increased (from 160.03 [n53] to
1.29 [n52]; Figure 8d) however, because of the absence of TRPV1-
immunolabeled neurons in one animal, the significance could not be
assessed.
Previous research has demonstrated that primary sensory neurons
in the DRG adjacent to the injured DRG also show phenotypic changes
(Hammond, Ackerman, Holdsworth, & Elzey, 2004; Hudson et al.,
2001). Therefore, we also assessed NAPE-PLD, TRPV1, CB1, receptor,
and FAAH immunostaining in the ipsilateral L4 DRG. We found no
FIGURE 7 Most primary sensory neurons expressing NAPE-PLD also express the CB1 receptor, TRPV1, and/or FAAH. (a–c) Typical combined
image (a) and separated images (b,c) of a section incubated with the anti-NAPE-PLD (b, green) and an anti-CB1 receptor (c, red) antibody. NAPE-
PLD shows a high degree of coexpression with the CB1 receptor. (d–f) A typical combined image (d) and separated images (e,f) of a section incu-
bated with the anti-NAPE-PLD (e, green) and an anti-TRPV1 (f, red) antibody. NAPE-PLD also shows a high degree of coexpression with TRPV1.
(g–i) A typical combined image (g) and separated images (h,i) of a section incubated with the anti-NAPE-PLD (h, green) and an anti-FAAH (i, red)
antibody. NAPE-PLD also shows a high degree of coexpression with FAAH. Arrowheads in (a, d, g) indicate NAPE-PLD/CB1 receptor-
coexpressing, NAPE-PLD/TRPV1-coexpressing, and NAPE-PLD/FAAH-immunopositive neurons, respectively. For quantified data, see Table 1.
All images are single scan images acquired with a320 objective lens (NA: 0.50) and a 47-mm pinhole aperture corresponding to 1.29 Airy units,
providing four 6-mm-thin optical sections. Scale bar550 mm
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significant change in the ratio of immunopositive cells for NAPE-PLD
(p5 .415), FAAH (p5 .454), or TRPV1 (p5 .166; two-tailed Fisher’s
exact test; Table 4). For the CB1 receptor, the significance level for the
reduction in the ratio of immunopositive cells was p5 .051 (Fisher’s
exact test; Table 4).
4 | DISCUSSION
The present study shows that about one-third of primary sensory neurons
in lumbar DRG express NAPE-PLD. The present data also show that
about two-thirds to three-quarters of the NAPE-PLD-expressing neurons
could be nociceptive because most of the NAPE-PLD-immunopositive
cells are small-diameter neurons that are nociceptive in function (Nagy
et al., 2004) and that 35%, 50%, and 60% of the NAPE-PLD-
expressing cells also express the nociceptive markers CGRP, IB4-binding
site, and TRPV1, respectively, (nota bene, CGRP, IB4-binding site, and
TRPV1 exhibit significant coexpression in DRG [Nagy et al., 2004]),
whereas only 30% of the cells express the nonnociceptive cell marker
heavy weight neurofilament NF200. These data are consistent with recent
findings showing that NAPE-PLD mRNA is expressed in primary sensory
neurons and that most of those neurons are sensitive to the archetypical
TRPV1 activator capsaicin (Bishay et al., 2010; Nagy et al., 2009).
FIGURE 8 Peripheral pathological conditions disturb the staining pattern observed in naive animals. (a) Correlation between NAPE-PLD
and CB1 receptor staining intensity of naive rat primary sensory neurons exhibiting coexpression of these two molecules. Note the high
correlation between the intensities of the two stainings. (b) Correlation between NAPE-PLD and TRPV1 immunostaining intensity of naive
rat primary sensory neurons exhibiting coexpression of these two molecules. Note the lack of correlation between the intensities of the
two stainings. (c) Correlation of NAPE-PLD immunostaining with immunostaining intensities for the CB1 receptor, TRPV1, and FAAH in ipsi-
lateral DRG under naive conditions (open bars) following injection of CFA (gray bars) into the paw or following SNL (black bar). Note that
the strong correlation between the staining intensities of the NAPE-PLD and CB1 receptor immunostaining observed in naive animals was
significantly reduced by both CFA injection and SNL (asterisks). (d) Ratio between staining intensities on the ipsilateral and contralateral
DRG for the various markers (NAPE-PLD, the CB1 receptor, TRPV1, and FAAH) under naive conditions (open bars) following CFA injection
(gray bars) and following SNL (black bars). Note that CFA injection significantly (asterisk) increases the ipsilateral–contralateral TRPV1 stain-
ing intensity. Although SNL appears to have the same effect because of the reduction in the number of TRPV1-immunopositive cells, the
ratio could be established only in two animals, and statistical analysis was not performed. All data are expressed as mean6 SEM
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Among the two major types of nociceptive primary sensory neu-
rons, NAPE-PLD exhibits preference for IB4-binding cells. IB4-binding
and peptidergic primary sensory neurons differ in their peripheral tissue
targets, spinal projections, membrane protein expression, responses to
painful events, and even in the brain areas where the information they
convey is transmitted (Bennett, Averill, Clary, Priestley, & McMahon,
1996; Breese, George, Pauers, & Stucky, 2005; Perry & Lawson, 1998;
Todd, 2010). Functionally, IB4-binding neurons are associated primarily
with responses to noxious mechanical stimuli and the development of
mechanical pain, although they may also contribute significantly to the
development of thermal pain following nerve injury (Cavanaugh et al.,
2009; Vilceanu, Honore, Hogan, & Stucky, 2010). Therefore, if NAPE-
PLD is involved in nociceptive processing in primary sensory neurons,
its activity could contribute to the regulation of mechanosensitivity
and the development of mechanical pain.
Among the putative enzymatic pathways that are implicated in
converting NAPE into N-acylethanolamine (NAEA), including ananda-
mide (Liu et al., 2006, 2008; Okamoto et al., 2004; Simon & Cravatt,
2006, 2008), the NAPE-PLD-catalyzed pathway is the only one known
to be Ca21-sensitive (Okamoto et al., 2004; Tsuboi et al., 2011; Ueda
et al., 2001; Wang et al., 2006, 2008). van der Stelt and colleagues
(2005) reported that increasing the intracellular Ca21 concentration
results in anandamide synthesis in cultured primary sensory neurons.
These data indicate that NAPE-PLD is functional in cultured primary
sensory neurons.
In addition to anandamide, related molecules, including palmitoyle-
thanolamine (PEA) and oleoylethanolamine (OEA), are also synthesized
by NAPE-PLD. Both PEA and OEA (and anandamide) activate the per-
oxisome proliferator-activated receptor-a (PPARa; Fu et al., 2003; Lo
Verme et al., 2005; Sun, Alexander, Kendall, & Bennett, 2006) and the
G protein-coupled receptor 119 (GPR119; Overton et al., 2006; Ryberg
et al., 2007). Furthermore, PEA (and anandamide) also activates GPR55
(Lauckner et al., 2008; Ryberg et al., 2007). Although PPARa is
expressed in both small- and large-diameter cells, GPR55 is expressed
primarily in NF200-expressing large-diameter cells (Lauckner et al.,
2008; Lo Verme et al., 2005). Therefore, the expression pattern of
NAPE-PLD that we found in the present study suggests that NAPE-
PLD, in addition to signaling through the CB1 receptor and TRPV1,
could also be involved in signaling through PPARa and GPR55 in sub-
populations of primary sensory neurons.
Consistent with the view that an autocrine signaling system that
involves anandamide, the CB1 receptor, and TRPV1 could exist in a
subpopulation of nociceptive primary sensory neurons (Sousa-Valente,
Varga, Ananthan, Khajuria, & Nagy, 2014), we have shown here that
FIGURE 9 Both CFA and IFA injection into the hind paw reduce
the number of NAPE-PLD-immunolabeled neurons without induc-
ing any change in the number of TRPV1-, CB1 receptor-, or FAAH-
immunolabeled neurons in DRG. Chart shows the relative number
of neurons exhibiting immunopositivity for NAPE-PLD, CB1 recep-
tor, TRPV1, and FAAH in naive (open bars), IFA-injected (gray
bars), and CFA-injected (black bars) animals. Both IFA and CFA
injection induced a small but significant reduction in the relative
number of neurons exhibiting immunopositivity for NAPE-PLD. The
number of immunopositive neurons for the other markers is not
changed either by IFA or by CFA injection. Asterisks indicate signif-
icant differences from naive (p5 .01 for IFA and p5 .02 for CFA
[n53 for both IFA and CFA], two-tailed Fisher’s exact test). All
data are expressed as mean6 SEM
TABLE 2 Summary of the proportion of neurons expressing NAPE-PLD and other markers in L4–5 DRG from IFA-injected and CFA-injected
animalsa
Number of cells
used for analysis
Percentage of NAPE-PLD-
expressing cells expressing
various markers (p value)
Percentage of neurons expressing
various markers together
with NAPE-PLD (p value)
NAPE-PLD IFA 3,872 3560.5 (.09)b -
CFA 4,181 3560.6 (.12)b -
TRPV1 IFA 1,392 4260.2 (.92)b 546 6.4 (.31)b
CFA 1,625 4362.2 (.74)b 626 1.6 (.67)b
CB1 IFA 1,006 3560.7 (.56)b 616 1.0 (.40)b
CFA 1,301 3360.9 (.66)b 656 6.4 (.17)b
FAAH IFA 1,474 3560.5 (.77)b 766 9.0 (.16)b
CFA 1,255 3660.8 (.52)b 696 10.6 (.59)b
aN53 for each data point.
bTwo-tailed Fisher exact test showing statistical differences at p< .05.
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NAPE-PLD exhibits a high degree of coexpression with both TRPV1
and the CB1 receptor. We have also demonstrated here that NAPE-
PLD shows a high degree of coexpression with FAAH, which is
expressed in the majority of TRPV1-expressing primary sensory neu-
rons (Lever et al., 2009). Considering the coexpression patterns we
found in the present study together with those published previously on
TRPV1 and the CB1 receptor and on TRPV1 and FAAH coexpression
(Agarwal et al., 2007; Ahluwalia et al., 2000; Binzen et al., 2006; Lever
et al., 2009; Mitrirattanakul et al., 2006), it appears that the anatomical
basis for an anandamide-, TRPV1-, CB1 receptor-, and FAAH-mediated
autocrine signaling system indeed exists in the majority of nociceptive
primary sensory neurons. Our recent finding that TRPV1 shows a high
degree of coexpression with some of the enzymes implicated in Ca21-
insensitive anandamide synthesis (Varga et al., 2014) suggests that
anandamide could be synthesized both in Ca21-sensitive and in Ca21-
insensitive manners in at least some of those primary sensory neurons.
Although TRPV1 activation by anandamide results in excitation
(Ahluwalia et al., 2003; Potenzieri, Brink, & Simone, 2009; Zygmunt
et al., 1999), CB1 receptor activation by this agent is generally consid-
ered as inhibitory in nociceptive primary sensory neurons (Calignano,
FIGURE 10 Ligation of the L5 spinal nerve induces reduction in the number of neurons exhibiting immunopositivity of NAPE-PLD, TRPV1, and the
CB1 receptor, whereas it induces an increase in the number of neurons exhibiting immunopositivity of FAAH in the L5 DRG. (a) Typical images of
DRG sections cut from the ipsilateral (IPSI) L5 DRG of a sham-operated rat (SHAM) and animals subjected to ligation of the L5 spinal nerve (SNL) and
incubated in anti-NAPE-PLD, anti-CB1 receptor, anti-TRPV1, and anti-FAAH antibodies. The numbers of cells exhibiting immunopositivity for NAPE-
PLD, the CB1 receptor, and TRPV1 were reduced following SNL, whereas the number of cells exhibiting immunopositivity for FAAHwas increased
following SNL. (b) Comparison among the number of primary sensory neurons exhibiting immunopositivity for NAPE-PLD, CB1 receptor, TRPV1, and
FAAH in the ipsilateral L5 DRG of naïve rats (open bars), sham-operated rats (gray bars), and rats subjected to L5 SNL (black bars). SNL reduces the
proportion of neurons expressing NAPE-PLD, TRPV1, and the CB1 receptor and increases the proportion of FAAH in the injured L5 DRG. (p< .001
for TRPV1, p< .001 for TRPV1, p< .001 for the CB1 receptor, and p<0.001 for FAAH, two-tailed Fisher’s exact test). In addition, the sham injury
also reduced the number of neurons exhibiting immunopositivity for NAPE-PLD. Scale bar550lm
TABLE 3 Summary of the proportion of neurons expressing NAPE-PLD and other markers in Ipsilateral L5 DRG from sham operated and
SNL Operated animalsa
Number of cells
used for analysis
Percentage of NAPE-PLD-
expressing cells expressing
various markers (p value)
Percentage of neurons expressing
various markers together
with NAPE-PLD (p value)
NAPE-PLD SHAM 1,932 3462.1 (.04)b -
SNL 1,962 1961.4 (.00)b -
TRPV1 SHAM 668 3963.4 (.48)b 616 8.8 (.60)b
SNL 695 666.2 (.00)b 56 10.1 (.00)b
CB1 SHAM 614 3361.2 (.92)b 596 6 (.04)b
SNL 653 1561.8 (.00)b 496 23.8 (.00)b
FAAH SHAM 650 3662.8 (.71)b 636 9.6 (1.00)b
SNL 614 5166.5 (.00)b 836 9.5 (.00)b
aN53 for each data point.
bTwo-tailed Fisher exact test showing statistical differences at p< .05.
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La Rana, Giuffrida, & Piomelli, 1998; Chen et al., 2016; Clapper et al.,
2010; Kelly, Jhaveri, Sagar, Kendall, & Chapman, 2003; Richardson,
Kilo, & Hargreaves, 1998). The CB1 receptor-mediated inhibitory effect
in those neurons results, inter alia, in the reduction of TRPV1-mediated
responses (Binzen et al., 2006; Mahmud, Santha, Paule, & Nagy, 2009;
Santha, Jenes, Somogyi, & Nagy, 2010). By hydrolyzing anandamide,
FAAH could serve as a brake in both the anandamide-induced TRPV1-
and CB1 receptor-mediated effects.
We recently showed that, although anandamide produced in a
Ca21-insensitive fashion in cultured primary sensory neurons induces
TRPV1-mediated excitation, it does not produce a CB1 receptor-
mediated inhibitory effect when the inhibitory effect is assessed by
measuring TRPV1-mediated responses (Varga et al., 2014). The finding
that Ca21-sensitive anandamide production in primary sensory neurons
results in TRPV1-mediated excitatory effects (van der Stelt et al., 2005)
suggests that NAPE-PLD activity could also be associated with TRPV1
activation. However, although we found a strong correlation between
NAPE-PLD- and CB1 receptor-immunostaining intensities, the correla-
tion between NAPE-PLD- and TRPV1-immunostaining intensities is
very low. These data suggest that, at least in intact DRG, NAPE-PLD
activity may be linked to the CB1 receptor rather than to TRPV1 acti-
vation. If, indeed, anandamide produced in a Ca21-sensitive and a
Ca21-insensitive manner has differing primary targets in primary sen-
sory neurons, the anandamide-, CB1 receptor-, TRPV1-, and FAAH-
formed putative autocrine signaling system could exert a very delicate
control over the activity of a major proportion of nociceptive cells and,
hence, over the development of pain. Consequently, any change in the
expression or activity of any members of that system could disturb bal-
anced signaling that may contribute to the development of pain.
Our data indicate that various types of painful disturbances of the
homeostasis of peripheral tissues are able to produce such perturba-
tion. Whereas CFA is used to induce a painful inflammatory reaction,
IFA is used as its control, although IFA injection itself induces some
inflammatory reaction and even hypersensitivity (Billiau & Matthys,
2001). Indeed, IFA injection induced a transient hypersensitivity in the
present study. Furthermore, similarly to CFA injection, IFA also induced
a small but nevertheless significant reduction in the number of NAPE-
PLD-immunolabeled cells as well as in the high correlation of intensities
between NAPE-PLD and CB1 receptor immunolabeling. Both IFA and
CFA increased the ipsilateral/contralateral intensity ratio of TRPV1
immunolabeling (i.e., increased in intensity of TRPV1 immunolabeling
on the ipsilateral side). The slight but significant reduction in the num-
ber of CB1 receptor-expressing cells produced by CFA and IFA is sur-
prising because this is opposite to what had been previously reported
(Amaya et al., 2006). Furthermore, the lack of increase in the number
of TRPV1-expressing cells is also surprising because it differs from data
that had been reported earlier (Amaya et al., 2004, 2006; Ji et al.,
2002; Luo et al., 2004; Yu et al., 2008; but see Bar et al., 2004; Zhou
et al., 2003). These differences could be due to the use of different
analyzing techniques in the different studies. Nevertheless, the com-
bined effects of the changes that we observed suggest that a balanced
signaling between anandamide of NAPE-PLD origin and TRPV1 and
the CB1 receptor is tipped toward a signaling with increased excitatory
and reduced inhibitory components. However, the contribution of this
unbalanced signaling could be negligible because, although the CFA
injection-induced hypersensitivity is significantly greater than that pro-
duced by IFA injection, the changes in the expression pattern of the
molecules are not.
A different type of perturbation of balanced endocannabinoid/
endovanilloid signaling occurs following peripheral nerve injury because
SNL reduces the number of NAPE-PLD- and CB1 receptor-expressing
neurons, whereas it increases the number of FAAH-immunolabeled
cells. These changes are expected to result in a dramatic reduction of
inhibitory signaling between anandamide of NAPE-PLD origin and the
CB1 receptor in the affected neurons. The nerve injury-induced down-
regulation of NAPE-PLD expression is consistent with a recent study
showing that NAPE-PLD mRNA expression is reduced in the injury-
affected DRG in another neuropathic pain model, the so-called spared
nerve injury model (Bishay et al., 2010). Nerve injury-induced downreg-
ulation of NAPE-PLD expression is associated with a reduction in
TABLE 4 Summary of the proportion of neurons expressing NAPE-PLD and other markers in ipsilateral L4 DRG from sham operated and
SNL operated animalsa
Number of cells
used for analysis
Percentage of NAPE-PLD-
expressing cells expressing
various markers (p value)
Percentage of neurons expressing
various markers together
with NAPE-PLD (p value)
NAPE-PLD SHAM 1,907 3661.1 (.29)b -
SNL 1,982 3862.7 (.85)b -
TRPV1 SHAM 631 4163.9 (.82)b 516 8.8 (.11)b
SNL 722 3666.3 (.12)b 566 6.2 (.89)b
CB1 SHAM 679 3360.8 (.85)b 566 14.9 (.02)b
SNL 618 4161.0 (.03)b 716 14.6 (.34)b
FAAH SHAM 597 3760.3 (.37)b 666 3.8 (.44)b
SNL 642 3861.4 (.96)b 636 10.7 (.89)b
aN53 for each data point.
bTwo-tailed Fisher exact test showing statistical differences at p< .05.
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NAEA content, including that of anandamide, of the affected DRG
(Bishay et al., 2010, 2013; Mitrirattanakul et al., 2006). The nerve
injury-induced upregulation of FAAH expression is also consistent with
results from previous studies (Bishay et al., 2010), although, in our ear-
lier study (Lever et al., 2009), the increase in the proportion of FAAH-
expressing neurons did not reach the level of significance. This discrep-
ancy between our present and previous data could be due to the tran-
sient nature of upregulation of FAAH expression, which reaches its
peak on the seventh day after the injury (Bishay et al., 2010). Although
we assessed nerve injury-induced changes 7 days after the surgery in
both studies, because of possible slight differences in surgery techni-
ques used by different persons, the time course of changes could be
different. Nevertheless, the changes we found in CB1 receptor expres-
sion are generally consistent with previous reports (Costigan et al.,
2002; Mitrirattanakul et al., 2006; Zhang et al., 2007). Finally, in addi-
tion to changes in the proportions of NAPE-PLD-, CB1 receptor-, and
FAAH-expressing neurons, the proportion of TRPV1-expressing DRG
neurons is also dramatically reduced by SNL. This change is similar to
that reported earlier by others who used the same neuropathic model
(Hudson et al., 2001; Lever et al., 2009). This reduced TRPV1 expres-
sion is consistent with the limited role of this ion channel in the devel-
opment of pain following peripheral nerve injury (Caterina et al., 2000).
In summary, this study shows that a major proportion of primary
sensory neurons express NAPE-PLD. We also show that NAPE-PLD
exhibits a high degree of coexpression with TRPV1, the CB1 receptor,
and FAAH, indicating that NAPE-PLD indeed could be involved in an
autocrine regulatory mechanism in a major proportion of nociceptive
primary sensory neurons. Finally, we show that, although peripheral
inflammation and injury to peripheral nerves induce differing changes
in the expression pattern of NAPE-PLD, the CB1 receptor, TRPV1, and
FAAH, both sets of changes are highly likely to produce unbalanced
signaling in that autocrine regulatory system and that unbalanced sig-
naling is characterized primarily by reduced anandamide-induced and
CB1 receptor-mediated activity and, hence, reduced inhibition on the
activity and excitability of primary sensory neurons. Similar unbalanced
endocannabinoid/endovanilloid signaling because of reduction in CB1
receptor-mediated inhibitory effects in primary sensory neurons as
well as in the spinal cord has been shown to contribute to the develop-
ment of pain in various animal models of persistent pain (Bishay et al.,
2010; Guasti et al., 2009; Jhaveri, Richardson, Kendall, Barrett, & Chap-
man, 2006; Khasabova et al., 2008, 2012, 2013; Starowicz & Przew-
locka, 2012; Starowicz et al., 2012, 2013).
The findings we present here provide the first insight into an auto-
crine signaling system that is highly likely to play an important role in
regulating the excitability of a major group of nociceptive primary sen-
sory neurons. This insight is important because it suggests that phar-
macological manipulation of this system might provide a significant
reduction in spinal nociceptive input and, hence, reduction in pain asso-
ciated with peripheral pathologies. However, full utilization of the puta-
tive analgesic potential of this system requires further elucidation of
the signaling mechanism. For example, we recently showed that spatial
proximity and protein–protein interactions between TRPV1 and the
CB1 receptor may determine how the CB1 receptor affects TRPV1
activity (Chen et al., 2016). Similarly, the spatial relationship between
FAAH and TRPV1 and/or the CB1 receptor, which is currently
unknown, is of high importance because it determines whether FAAH
activity directs anandamide away from the CB1 receptor or TRPV1.
Furthermore, although our data suggest that anandamide synthesized
by NAPE-PLD may preferentially activate the CB1 receptor, this
assumption requires further support.
It is also important to note that, to avoid inducing undesirable
effects, manipulation of the endocannabinoid/endovanilloid autocrine
signaling system even outside the blood–brain barrier should occur in a
cell-specific manner (i.e., in nociceptive primary sensory neurons)
because several components of the endocannabinoid/endovanilloid
system exhibit widespread expression patterns. Therefore, although
the CB1 receptor and TRPV1 outside the central nervous system are
expressed almost exclusively by nociceptive primary sensory neurons
(Agarwal et al., 2007; Ahluwalia et al., 2000; Binzen et al., 2006;
Caterina et al., 1997; Mitrirattanakul et al., 2006; Sousa-Valente,
Andreou, et al., 2014; Tominaga et al., 1998; Veress et al., 2013), both
NAPE-PLD and FAAH are expressed by various cells and are involved
in various physiological functions (Alhouayek & Muccioli, 2012; Geurts
et al., 2015; Guo et al., 2005; Paria, Zhao, Wang, Das, & Dey, 1999;
Rossi et al., 2009). Nevertheless, our data indicate that NAPE-PLD
could be another important molecule of the endocannabinoid/endova-
nilloid system that controls nociceptive processing in primary sensory
neurons. Therefore, we propose that NAPE-PLD in nociceptive primary
sensory neurons could be a valuable novel target for the development
of new analgesics.
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